Change in the Japanese pharmaceutical market: Cradle of innovation or grave of corporate profits?

McKinsey

Insights on Pharmaceuticals & Medical ProductsUnderstanding structural shifts in the market can help pharma stakeholders innovate and, ultimately, deliver benefits for patients.

How Precision Medicine Will Transform the Pharmaceutical and Healthcare Industries

Strategy+Business

And although the pharmaceutical and healthcare industries know this is the way forward, they face some significant hurdles Precision medicine combines business opportunities with clinical health benefits.

What’s behind the pharmaceutical sector’s M&A push

McKinsey

There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios. Strategy & Corporate Finance Insights

Innovating at the speed of the 21st century in pharmaceuticals

McKinsey

The CEO of Eli Lilly offers perspectives on accelerating change in the industry. Our Insights

Why the Pharmaceutical Industry is Booming in Japan - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN

Harvard Business

That rule of life is no secret to pharmaceutical companies across the globe. Japan remains the world’s second-biggest pharmaceuticals market, behind only the United States and China. The biggest change for pharma in Japan was the 2014 revision of the nation’s keystone pharmaceuticals law, renamed the PMD Act—for pharmaceutical and medical devices. Older people need more medicine.

Transforming Medical Affairs: Tapping the alchemy of storytellers and digital start-ups

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe Head of Digital Strategy and Medical Innovation, US Clinical Development and Medical Affairs at Novartis discusses how disruptive technologies and digital innovation are inspiring a start-up mind-set within the organization.

Divestiture in medtech: Are you the natural owner of your businesses?

McKinsey

Insights on Pharmaceuticals & Medical ProductsFor medtech companies, divestitures can create value. But several elements are necessary to make separations successful.

Improving patient adherence through data-driven insights

McKinsey

A McKinsey study points to areas pharmaceutical companies can address to combat this long-standing industry issue. Insights on Pharmaceuticals & Medical ProductsWhen patients fail to follow prescribed medical regimens, outcomes suffer.

Building digital ecosystems in Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsTwo Merck Healthcare digital specialists explain their company’s transformation and the impact it has had on patients.

The rise and rise of medtech in Asia

McKinsey

Insights on Pharmaceuticals & Medical ProductsHow can medtech companies thrive in the world’s fastest-growing market?

Digitization, automation, and online testing: The future of pharma quality control

McKinsey

Insights on Pharmaceuticals & Medical ProductsEmerging technologies can make quality control (QC) faster and more efficient. What do pharma companies need to do to become QC leaders?

Precision medicine: Opening the aperture

McKinsey

Insights on Pharmaceuticals & Medical ProductsTo keep pace with the evolving ecosystem for precision medicine, pharma players must be attuned to three crucial components: data collection, individualized solutions, and supporting business models.

Data 87

How new biomolecular platforms and digital technologies are changing R&D

McKinsey

By going digital, biotech pioneers with promising biomolecular platforms are improving drug discovery and development—and changing the pharmaceutical industry. Insights on Pharmaceuticals & Medical Products

Developing tomorrow’s leaders in life sciences

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn a sector undergoing unprecedented change, five muscles will define the successful leaders of the future.

Leading change in the Japanese pharma market: Innovating for the future in an uncertain present

McKinsey

Insights on Pharmaceuticals & Medical ProductsJacques Nathan, president of Sanofi Japan, discusses what’s ahead for his changing sector.

The digital imperative for pharma companies in Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsFive facts showing that companies should invest in digital customer engagement in Japan.

Genetic testing: Opportunities to unlock value in precision medicine

McKinsey

Insights on Pharmaceuticals & Medical ProductsAdvanced analysis of genomic data integrated with electronic medical records and other data sets, combined with effective reimbursement strategies and full data-regulatory compliance, will distinguish winning diagnostics companies.

Data 86

R&D in the ‘age of agile’

McKinsey

Insights on Pharmaceuticals & Medical ProductsAs innovation reshapes the pharma landscape, pharma companies will need to revisit their R&D operating models to thrive.

Agile 68

Barriers to Digital@Scale: Shifting the focus from tech to culture

McKinsey

Insights on Pharmaceuticals & Medical ProductsMany pharma and medtech companies have a digital strategy. But to pull off a true digital transformation, it's crucial to focus on culture and mindset, according to leaders who attended a recent European roundtable.

The changing face of medical-device design

McKinsey

Insights on Pharmaceuticals & Medical ProductsDesign can help craft a standout patient experience. Here, three leaders discuss how the discipline is improving medical products and driving innovation.

Operations as a competitive advantage in biotechnology

McKinsey

Insights on Pharmaceuticals & Medical ProductsEsteban Santos, executive vice president for operations at Amgen, explains how the company is using operations to support innovation.

Collaborating to address our global public health challenges

McKinsey

Insights on Pharmaceuticals & Medical ProductsJaak Peeters, head of global public health at Johnson & Johnson, discusses the role pharma can play in addressing big challenges, such as fighting diseases like HIV and tuberculosis.

Helping to accelerate cures: Regulating the rapidly evolving field of cell and gene therapies

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn this interview, Peter Marks of the US Food and Drug Administration discusses how the organization has contributed to the broader ecosystem of innovation.

Medical affairs: Key imperatives for engaging and educating physicians in a digital world

McKinsey

Insights on Pharmaceuticals & Medical ProductsFive strategic efforts can help medical affairs teams master customer engagement in the digital age.

Real-world evidence: Driving a new drug-development paradigm in oncology

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.

Digital R&D: The Next Frontier for Biopharmaceuticals

McKinsey

Insights on Pharmaceuticals & Medical ProductsDigital promises to transform R&D productivity over the next decade. What will it take to realize this potential?

The European public-procurement opportunity: Delivering value in medtech

McKinsey

Insights on Pharmaceuticals & Medical ProductsValue-based procurement is a reality today. To capture the opportunity in today’s European medtech-public-procurement market fully, winners need to adapt to new realities quickly.

Asia on the move: Five trends shaping the Asia biopharmaceutical market

McKinsey

Insights on Pharmaceuticals & Medical ProductsEnthusiasm for the biopharmaceutical sector in Asia has been flat, due in part to China’s market-access blockade, Japan’s spending controls, and deceleration in India and Southeast Asia.

From product to customer experience: The new way to launch in pharma

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn increasingly crowded drug markets, a strong clinical profile is no longer enough to ensure a distinctive launch. To be successful, pharma companies need to launch not only products but also experiences.

Real-world evidence: From activity to impact in healthcare decision making

McKinsey

Insights on Pharmaceuticals & Medical ProductsWhile there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.

Digitization, automation, and online testing: The future of pharma quality control

McKinsey

Insights on Pharmaceuticals & Medical ProductsEmerging technologies can make quality control (QC) faster and more efficient. What do pharma companies need to do to become QC leaders?

Designing a healthy future for medical devices

McKinsey

Insights on Pharmaceuticals & Medical ProductsDesign is increasingly a business imperative, but medtech companies have been slow to embrace it. What benefits might a focus on medical-device design bring, and how can companies get started?

Five things to know about biosimilars right now

McKinsey

Insights on Pharmaceuticals & Medical ProductsIn the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart?

Launches in oncology: The elements of success

McKinsey

Insights on Pharmaceuticals & Medical ProductsAs the prevalence and severity of cancer has increased, the drug landscape has shifted. Oncology launches are increasingly critical and require a dedicated approach. Here’s what it entails.

Drug Pricing in the United States

Tom Spencer

1 Pharmaceutical companies are unique in their capacity, due to little regulation and oversight, to raise prices. Pharmaceutical companies focus on a variety of factors when pricing drugs with the main objective of generating the most revenue. Topic: Pharmaceutical Industry in the U.S.”

How pharma manufacturers can enhance their medical information teams

McKinsey

Insights on Pharmaceuticals & Medical ProductsMedical information teams can be a source of differentiation if used strategically. But the evolving environment means pharma manufacturers will need to make organizational enhancements to get ahead.

What’s next for Japan’s pharma market

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe president of Merck in Japan discusses how healthcare players in the country can capitalize on early detection rates and use collaboration to drive innovation.

The evolving role of medical affairs in Asia?Pacific: Three imperatives for pharmacos

McKinsey

Insights on Pharmaceuticals & Medical ProductsMedical affairs is poised for a broader, more strategic role. However, leaders will need to ramp up new types of capabilities and talent to achieve this ambition.

From semiconductors to life sciences: Building a global business out of Japan

McKinsey

Insights on Pharmaceuticals & Medical ProductsThe president and CEO of JSR Corporation discusses the company’s plans to grow a global healthcare franchise building from his lessons in the semiconductor industry.

Should sub-Saharan Africa make its own drugs?

McKinsey

A comprehensive analysis of the business, economic, and public-health impact finds the potential for local production of pharmaceuticals to be a mixed bag. Public Sector Insights